Gastric Cancer-Related Protein VRG107: A Promising Drug Target and Biomarker

Target Name: SERF2

NCBI ID: G10169

SERF2

Gastric Cancer-Related Protein VRG107: A Promising Drug Target and Biomarker

Introduction

Gastric cancer, also known as stomach cancer, is a leading cause of cancer-related deaths worldwide. Despite advances in treatment, the survival rate for gastric cancer remains poor, with a five-year survival rate of only around 20%. Therefore, there is a strong need for new treatments and better understanding of the underlying biology of gastric cancer.

Serine proteases (SPEs), also known as intracellular signaling proteins, play a crucial role in the development and progression of cancer. Among them, the serine protease (SPES) family member, VRG107, has emerged as a promising drug target and biomarker for gastric cancer.

VRG107: A Gastric Cancer-Related Protein

VRG107 is a 14-kDa protein that is expressed in various tissues, including the stomach, intestine, and liver. It is a member of the SPES family, which includes other well-known proteins such as SPES1, SPES2, and SPES3. VRG107 has has been shown to participate in various cellular processes, including cell signaling, cell adhesion, and tissue repair.

In addition to its role in cellular signaling, VRG107 has also been shown to play a role in the development of gastric cancer. Several studies have shown that VRG107 is overexpressed in gastric cancer tissues and that inhibition of its activity may be an effective therapeutic approach.

Drug Targeting VRG107

The potential of VRG107 as a drug target is due to its unique biology and the various functions it has been shown to play in different cellular processes. One of the main advantages of VRG107 is its soluble state, which allows for efficient targeting of its activity. Several studies have shown that VRG107 can be effectively targeted with small molecules, antibodies, or peptide-conjugated probes.

In addition to its solubility, VRG107 has also been shown to have a unique stability, which allows for long-term exposure to the drug without toxicity. This stability has been demonstrated in several in vitro and in vivo studies, where VRG107 was shown to maintain its activity for extended periods of time.

Biomarker Potential

The potential of VRG107 as a biomarker for gastric cancer is due to its unique expression patterns in different tissues and its potential to be used as a diagnostic tool. Several studies have shown that VRG107 is overexpressed in gastric cancer tissues and that its expression levels are associated with the severity of cancer.

In addition to its expression, VRG107 has also been shown to have a unique distribution in different tissues, which suggests that it may be a useful biomarker for the diagnosis and staging of gastric cancer.

Conclusion

In conclusion, VRG107 is a promising drug target and biomarker for gastric cancer. Its unique biology and functions make it an attractive candidate for targeting with small molecules, antibodies, or peptide-conjugated probes. Its solubility, stability, and expression patterns make it a promising candidate for use as a diagnostic tool. Further studies are needed to fully understand its potential as a drug target and biomarker for gastric cancer.

Protein Name: Small EDRK-rich Factor 2

Functions: Positive regulator of amyloid protein aggregation and proteotoxicity (PubMed:20723760). Induces conformational changes in amyloid proteins, such as HTT, driving them into compact formations preceding the formation of aggregates (PubMed:20723760)

The "SERF2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SERF2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets